IP Verse

Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens And Uses Thereof - EP3096785

The patent EP3096785 was granted to Pfizer on Sep 9, 2020. The application was originally filed on Jan 15, 2015 under application number EP15708580A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3096785

PFIZER
Application Number
EP15708580A
Filing Date
Jan 15, 2015
Status
Granted And Under Opposition
Aug 7, 2020
Grant Date
Sep 9, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SK BIOSCIENCEJun 9, 2021ZWICKERADMISSIBLE
SANOFI PASTEURJun 8, 2021ZWICKERADMISSIBLE
MERCK SHARP & DOHMEJun 4, 2021VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBWITHDRAWN

Patent Citations (95) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONCN103495161
DESCRIPTIONEP0372501
DESCRIPTIONEP0378881
DESCRIPTIONEP0427347
DESCRIPTIONEP0471177
DESCRIPTIONEP0594610
DESCRIPTIONEP0689454
DESCRIPTIONEP0735898
DESCRIPTIONEP0761231
DESCRIPTIONEP0835318
DESCRIPTIONGB2220221
DESCRIPTIONUS2006228380
DESCRIPTIONUS2006228381
DESCRIPTIONUS2007184071
DESCRIPTIONUS2007184072
DESCRIPTIONUS2007231340
DESCRIPTIONUS2008102498
DESCRIPTIONUS2008286838
DESCRIPTIONUS4709017
DESCRIPTIONUS4950740
DESCRIPTIONUS5614382
DESCRIPTIONUS5843711
DESCRIPTIONUS5917017
DESCRIPTIONUS6194388
DESCRIPTIONUS6207646
DESCRIPTIONUS6214806
DESCRIPTIONUS6218371
DESCRIPTIONUS6239116
DESCRIPTIONUS6339068
DESCRIPTIONUS6455673
DESCRIPTIONWO0007621
DESCRIPTIONWO0023105
DESCRIPTIONWO0037105
DESCRIPTIONWO0039299
DESCRIPTIONWO0041720
DESCRIPTIONWO0048630
DESCRIPTIONWO0056357
DESCRIPTIONWO0056358
DESCRIPTIONWO0061761
DESCRIPTIONWO0062800
DESCRIPTIONWO0121152
DESCRIPTIONWO0121207
DESCRIPTIONWO0172337
DESCRIPTIONWO0198334
DESCRIPTIONWO02091998
DESCRIPTIONWO03024480
DESCRIPTIONWO03054007
DESCRIPTIONWO2004081515
DESCRIPTIONWO2004083251
DESCRIPTIONWO2005033148
DESCRIPTIONWO2006032499
DESCRIPTIONWO2006110352
DESCRIPTIONWO2006110381
DESCRIPTIONWO2006134423
DESCRIPTIONWO2007026190
DESCRIPTIONWO2008079653
DESCRIPTIONWO2008118752
DESCRIPTIONWO2008143709
DESCRIPTIONWO2009000826
DESCRIPTIONWO2010125480
DESCRIPTIONWO2014027302
DESCRIPTIONWO2014097099
DESCRIPTIONWO9003184
DESCRIPTIONWO9101146
DESCRIPTIONWO9315760
DESCRIPTIONWO9317712
DESCRIPTIONWO9403208
DESCRIPTIONWO9508348
DESCRIPTIONWO9602555
DESCRIPTIONWO9611711
DESCRIPTIONWO9629094
DESCRIPTIONWO9818810
DESCRIPTIONWO9836772
DESCRIPTIONWO9842721
DESCRIPTIONWO9857659
DESCRIPTIONWO9858668
DESCRIPTIONWO9911241
DESCRIPTIONWO9944636
DESCRIPTIONWO9952549
EXAMINATIONUS2012321658
EXAMINATIONWO2007071711
EXAMINATIONWO2009000824
INTERNATIONAL-SEARCH-REPORTUS2013273098
INTERNATIONAL-SEARCH-REPORTWO2008079653
INTERNATIONAL-SEARCH-REPORTWO2008157590
INTERNATIONAL-SEARCH-REPORTWO2014118201
OPPOSITIONUS2012321660
OPPOSITIONUS2013344103
OPPOSITIONUS9492559
OPPOSITIONWO2007071711
OPPOSITIONWO2008079732
OPPOSITIONWO2009000825
OPPOSITIONWO2011100151
OPPOSITIONWO2014027302
OPPOSITIONWO2014097099

Non-Patent Literature (NPL) Citations (47) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BARALDOI ET AL., INFECT IMMUN, (2004), vol. 72, pages 4884 - 4887-
DESCRIPTION- BETHELL ET AL., BIOL. CHERN., (1979), vol. 254, pages 2572 - 2574-
DESCRIPTION- BETHELL ET AL., J. BIOL. CHERN., (1979), vol. 254, pages 2572 - 2574-
DESCRIPTION- CALIX ET AL., J BACTERIOL., (2011), vol. 193, no. 19, pages 5271 - 5278-
DESCRIPTION- CROOKE ET AL., ANNU. REV. PHARMACOL. TOXICOL, (1996), vol. 36, pages 107 - 129-
DESCRIPTION- DOUGLAS ET AL., J. BACTERIOL., (1987), vol. 169, no. 11, pages 4967 - 4971-
DESCRIPTION- FALUGI ET AL., EUR J IMMUNOL, (2001), vol. 31, pages 3816 - 3824-
DESCRIPTION- HEARN ET AL., J. CHROMATOGR, (1981), vol. 218, pages 509 - 518-
DESCRIPTION- HEARN ET AL., J. CHROMATOGR., (1981), vol. 218, pages 509 - 518-
DESCRIPTION- HESTRIN, S., J. BIOL. CHEM., (1949), vol. 180, pages 249 - 261-
DESCRIPTION- HU ET AL., CLIN DIAGN LAB IMMUNOL, (2005), vol. 122, pages 287 - 295-
DESCRIPTION- HU ET AL., CLIN DIAGN LAB IMMUNOL, (2005), vol. 12, no. 2, pages 287 - 295-
DESCRIPTION- HUNZIKER ET AL., MOD. SYNTH. METHODS, (1995), vol. 7, pages 331 - 417-
DESCRIPTION- JONES, C., CARBOHYDRATE RESEARCH, (2005), vol. 269, no. 1, pages 175 - 181-
DESCRIPTION- JONES ET AL., CARBOHYDRATE RESEARCH, (2005), vol. 340, no. 3, pages 403 - 409-
DESCRIPTION- JONES ET AL., J. PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, (2002), vol. 30, pages 1233 - 1247-
DESCRIPTION- JONES ET AL., THE JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (1957), vol. 79, no. 11, pages 2787 - 2793-
DESCRIPTION- KUO ET AL., INFECT IMMUN, (1995), vol. 63, pages 2706 - 2713-
DESCRIPTION- LEMERCINIER ET AL., CARBOHYDRATE RESEARCH, (1996), vol. 296, pages 83 - 96-
DESCRIPTION- LEMERCINIER ET AL., CARBOHYDRATE RESEARCH, (2006), vol. 341, no. 1, pages 68 - 74-
DESCRIPTION- LEONTEIN ET AL., CARBOHYDRATE RESEARCH, (1983), vol. 114, no. 2, pages 257 - 266-
DESCRIPTION- RICHARDS ET AL., ADV. EXP. MED. BIOL., (1988), vol. 228, pages 595 - 597-
DESCRIPTION- RICHARDS ET AL., CANADIAN JOURNAL OF CHEMISTRY, (1989), vol. 67, no. 6, pages 1038 - 1050-
DESCRIPTION- SJÖLANDER ET AL., J. LEUKOCYTE BIOL., (1998), vol. 64, page 713-
DESCRIPTION- UCHIDA ET AL., J. BIOL. CHEM., (1973), vol. 218, pages 3838 - 3844-
DESCRIPTION- UCHIDA ET AL., NATURE NEW BIOLOGY, (1971), vol. 233, pages 8 - 11-
DESCRIPTION- UHLMANN ET AL., Chem. Rev., HUMANA PRESS, (1990), vol. 90, page 543-
EXAMINATION- JULIE M SKINNER ET AL, "Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 48, doi:10.1016/J.VACCINE.2011.09.078, ISSN 0264-410X, (20110920), pages 8870 - 8876, (20110922), XP028326015
INTERNATIONAL-SEARCH-REPORT- OOSTERHUIS-KAFEJA ET AL, "Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006)", VACCINE, ELSEVIER LTD, GB, (20070213), vol. 25, no. 12, doi:10.1016/J.VACCINE.2006.11.032, ISSN 0264-410X, pages 2194 - 2212, XP005886439 [Y] 1,2,11,135-139,141,168-180,189-234 * See e.g. the abstract *
OPPOSITION- BLAKE et al., "Chapter 12 - Pneumococcal Vaccines: Manufacture and Quality Control for Product Release", BLAKE et al., Siber et al., Pneumococcal Vaccines: the Impact of Conjugate Vaccine, (20080000), pages 175 - 182, XP055817834-
OPPOSITION- BROWN et al., "Characterization of Complex Prophylactic Vaccines with Protein and Glycoconjugate Components", PP-Presentation 9th CASSS Symposium, (20120912), pages 1 - 34, XP055817799-
OPPOSITION- HSIEH et al., "Characterization of Saccharide-CRM197 Conjugate Vaccines", Physico-Chemical Procedures for the Characterization of Vaccines, Dev. Biol., Basel, (2000), vol. 103, pages 93 - 104, XP055817770-
OPPOSITION- JONES, "Chapter 5 - Stability and Degradation Pathways of Polysaccharide And Glycoconjugate Vaccines", JONES, Stephen E Harding, Stability of Complex Carbohydrate Structures - Biofuels, Foods, Vaccines and Shipwrecks, (20130207), pages 56 - 67, XP055817829-
OPPOSITION- JONES et al., "Spectroscopic Studies of the Structure and Stability of Glycoconjugate Vaccines", Bev. Biol. Basel, Karger, (20000000), vol. 103, pages 121 - 136-
OPPOSITION- JONES et al., "Spectroscopic Studies of the Structure and Stability of Glycoconjugate Vaccines", JONES et al., Brown et al., Physico-Chemical Procedures for the Characterization of Vaccines, (20000000), vol. 103, pages 121 - 136, XP055817860-
OPPOSITION- KLUGMAN et al., "Chapter 25 - Pneumococcal conjugate vaccine and pneumococcal common protein vaccines", KLUGMAN et al., Plotkin et al., Vaccines, 6th ed., (20130131), pages 504 - 541, XP055817845-
OPPOSITION- LEES et al., "Chapter 11: Conjugation Chemistry", LEES et al., Siber et al., PNEUMOCOCCAL VACCINES: THE IMPACT OF CONJUGATE VACCINE, Washington, (20080000), pages 163 - 173, XP055467636-
OPPOSITION- RICHARDS et al., "Structural analysis of the specific capsular polysaccharide of Streptococcus pneumoniae type 22F", Can. J. Chem., (19890000), vol. 67, pages 1038 - 1050, XP055817819-
OPPOSITION- V. TURULA et al., "The Application of SEC-MALS in Vaccine Development", PP-Presentation International Light Scattering Colloquium 2007 Wyatt Technology, (20071015), XP055817807-
OPPOSITION- WESSELS et al., "Structural Properties of Group B 1998 Streptococcal Type III Polysaccharide Conjugate Vaccines That Influence Immunogenicity and Efficacy", Infection and Immunity, vol. 66, no. 5, pages 2186 - 2192, XP009113849-
OPPOSITION- WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION, 60TH REPORT, WHO TECHNICAL REPORT SERIES, (2013), 977-
OPPOSITION- FRASCH, "Preparation of bacterial polysaccharide- June 24, 2009 protein conjugates: Analytical and manufacturing challenges", Vaccine, vol. 27, doi:10.1016/j.vaccine.2009.06.013, pages 6468 - 6470, XP026704485
OPPOSITION- SKINNER et al., "Pre-clinical evaluation of a 15-valent 2011 pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model", Vaccine, (20110000), vol. 29, doi:10.1016/j.vaccine.2011.09.078, pages 8870 - 8876, XP028326015
OPPOSITION- OVERTURF, "Pneumococcal Vaccination of Children", Seminars in Pediatric Infectious Diseases, (20020000), vol. 13, no. 3, doi:10.1053/spid.2002.125858, pages 155 - 164, XP055330430
OPPOSITION- JACOBS et al., "Emergence of Streptococcus pneumoniae Serotypes 19A, 6C, and 22F and Serogroup 15 in Cleveland, Ohio, in Relation to Introduction of the Protein‐Conjugated Pneumococcal Vaccine", Clinical Infectious Diseases, (20080000), vol. 47, doi:10.1086/592972, pages 1388 - 1395, XP055187199
OPPOSITION- FLASCHE et al., "Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study", PLoS ONE, (20110405), vol. 7, no. 7, pages 1 - 10, XP055817850
OPPOSITION- JONES, "Vaccines based on the cell surface 2005 carbohydrates of pathogenic bacteria", Anais da Academia Brasileira de Ciências, vol. 77, no. 2, doi:10.1590/S0001-37652005000200009, pages 293 - 324, XP008092732

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents